4Filed Sep 16, 8:00 PM ET
Apollomics (APLM) CEO Chen Hung-Wen Receives Award, Exercises RSUs
$APLM · Apollomics Inc.Research Summary
AI-generated summary of this SEC filing
Apollomics (APLM) CEO Chen Hung-Wen Receives Award, Exercises RSUs
What Happened
- Chen Hung‑Wen, CEO of Apollomics Inc., reported derivative activity and a grant: a 5,000‑share restricted stock unit (RSU) conversion/vesting on Sept 15, 2026, and an 8,000‑share option award on Sept 14, 2026. The Form 4 shows the 5,000 shares both acquired (conversion/exercise, code M) and disposed (code M) on Sept 15 at $0.00; the 8,000‑share award (code A) is recorded at $0.00. No cash consideration or dollar values were reported for these transactions.
Key Details
- Transactions:
- Sept 14, 2026 — Grant/Award (A): 8,000 shares (reported at $0.00). This is an option grant under the Apollomics 2023 Incentive Award Plan.
- Sept 15, 2026 — Exercise/Conversion (M): 5,000 shares acquired (reported at $0.00).
- Sept 15, 2026 — Exercise/Conversion (M): 5,000 shares disposed (reported at $0.00).
- Vesting/award terms:
- The 8,000‑share option vests over one year: 50% on March 14, 2027 and 50% on Sept 14, 2027 (per footnote).
- Each RSU represents a contingent right to one Class A ordinary share; the reported Sept 15 action corresponds to the vesting/conversion of 5,000 RSUs (footnote).
- Ownership/disclaimer: The filer is associated with King Regent Management Limited and disclaims beneficial ownership of shares held by that entity except for any pecuniary interest (footnote).
- Shares owned after the transactions: not specified in the filing.
- Timeliness: Form filed Sept 17, 2026 for transactions on Sept 14–15, 2026; filing does not indicate a late report.
Context
- The Sept 15 entries show a conversion/acquisition and a same‑day disposal of the 5,000 shares at $0.00. The Form 4 does not report sale proceeds or indicate an open‑market sale; such matching entries commonly reflect award settlement mechanics (e.g., conversion/settlement or internal transfer) rather than a market sell, but the filing provides no further detail. The 8,000‑share option grant is a standard equity award with a one‑year vesting schedule and does not reflect an immediate purchase or sale.